A Phase 3 interventional study of Umeclidinium bromide 62.5mcg and Umeclidinium bromide 125mcg in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 73 sites in 4 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2018-01-29.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline — 7 open to participants now, 8 under way, 5 of them phase 3. Pulmonary Disease, Chronic Obstructive · GlaxoSmithKline.
Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, this one is the 48th largest by enrollment of the 236 interventional ones that give a count, is one of 20 that started in 2013, is one of 65 in phase 3, and was the 164th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →7 of the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States, Argentina
Ages 40–80
GlaxoSmithKline · Sites in United States, Japan
Ages 40–80
GlaxoSmithKline · Sites in United Kingdom
Ages 18–55 · Healthy volunteers
GlaxoSmithKline · Sites in United States, Australia, Bulgaria and 10 more countries
Ages 40–75
GlaxoSmithKline · Sites in United States, Argentina, Australia and 13 more countries
Ages 40–80
By country, each count listing its studies:
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
276 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 84 · Phase 2 47 · Phase 3 65 · Phase 4 38
First in 2000; this study’s year is marked. 20 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 617 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 101 across the 236 interventional studies, 1,248 across the 40 observational. Of the 264 that completed or were terminated, 141 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
2 of the studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06154837GlaxoSmithKlineA Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease | 2026-12-16 |
| NCT07789899GlaxoSmithKlineA Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Two GSK3862995B Formulations in Healthy Participants | 2027-09-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this 12 week study is to evaluate the effects of the addition of umeclidinium bromide (62.5mcg) once-daily to fluticanse propionate/salmeterol (250/50mcg) twice-daily, umeclidinium bromide (125mcg) once-daily to fluticanse propionate/salmeterol (250/50mcg) twice-daily versus placebo to fluticanse propionate/salmeterol (250/50mcg) twice-daily on lung function, COPD-related health status assessments and safety in COPD subjects.
This is a mutlicenter, randomized, double-blind, parallell-group study. Subejcts who meet the eligibility criteria at screening and meet the randomization criteria at the end of a 4 week run-in period will enter a 12 week treatment period. There will be a 7 day follow-up period after the treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Specific ECG findings that preclude subject eligibility are listed in Appendix 4. The study investigator will determine the medical significance of any ECG abnormalities not listed in Appendix 4.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Long-acting muscarinic antagonist (LAMA), 62.5mcg plus Inhaled corticosteriod (ICS), 250mcg/ Long acting Beta agonist (LABA), 50mcg
Drug: Umeclidinium bromide 62.5mcg · Drug: Fluticasone propionate 250mcg/Salmeterol 50mcg
Long-acting muscarinic antagonist (LAMA), 125mcg plus Inhaled corticosteriod (ICS), 250mcg/ Long acting Beta agonist (LABA), 50mcg
Drug: Umeclidinium bromide 125mcg · Drug: Fluticasone propionate 250mcg/Salmeterol 50mcg
Inhaled corticosteriod (ICS), 250mcg/ Long acting Beta agonist (LABA), 50mcg
Drug: Fluticasone propionate 250mcg/Salmeterol 50mcg · Drug: Placebo
Inhalation Powder, LAMA 62.5mcg
Inhalation Powder, LAMA 125mcg
Drug page: Fluticasone
Inhalation Powder, ICS/LABA
Inhalation Powder, Placebo
Change From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) on Day 85
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on Treatment Day 85 is defined as the mean of the FEV1 values obtained 23 and 24 hours after dosing on Treatment Day 84 (i.e., at Week 12). Baseline trough FEV1 is the mean of the two assessments made at -30 and -5 minutes (min) pre-dose on Treatment Day 1. Change from Baseline was calculated as the Day 85 value minus the Baseline value. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessments made at -30 and -5 min pre-dose on Treatment Day 1), smoking status, day, day by Baseline and day by treatment interactions.
Time frame: Baseline and Day 85
Change From Baseline in Weighted Mean 0-6 Hour FEV1 Obtained Post-dose at Day 84
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The weighted mean FEV1 was derived by calculating the area under the curve, and then dividing the value by the relevant time interval. The weighted mean was calculated using the 24-hour serial FEV1 measurements at Day 84, which included pre-dose, and post-dose at 15 min, 30 min, 1 hour, 3 hours, and 6 hours. Baseline trough FEV1 is the mean of the two assessments made at -30 and -5 min pre-dose on Treatment Day 1. Change from Baseline was calculated as the Day 84 value minus the Baseline value. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessments made at -30and -5 min pre-dose on Treatment Day 1), smoking status, day, day by Baseline and day by treatment interactions.
Time frame: Baseline and Day 84
Change From Baseline in the Mean Percentage of Rescue-free Days Over Weeks 1-12
A rescue-free day is defined as a day on which no rescue medication was taken. Baseline calculations include a period of the later of 27 days before Visit 2 and the day after Visit 1, up to and including Day 1. The Weeks 1-12 calculations include a period from Study Day 2 up to the earlier of Study Day 85 and the day before Visit 7. Change from Baseline was calculated as the Weeks 1-12 value minus the Baseline value.
Time frame: Baseline and Weeks 1-12
Change From Baseline in the Mean Number of Puffs Per Day of Rescue Albuterol/Salbutamol Over Weeks 1-12
The mean number of puffs per day of rescue albuterol/salbutamol at Baseline and on-treatment was recorded. The total puffs of rescue albuterol/salbutamol for each day was calculated as: (number of puffs + \[2 \* number of nebules\]). Baseline calculations include a period of the later of 27 days before Visit 2 and the day after Visit 1, up to and including Day 1. The Weeks 1-12 calculations include a period from Study Day 2 up to the earlier of Study Day 85 and the day before Visit 7. Change from Baseline was calculated as the Weeks 1-12 value value minus the Baseline value. Analysis was performed using an analysis of covariance (ANCOVA) model with covariates of treatment, Baseline (mean during the 4 weeks prior to Day 1), and smoking status.
Time frame: Baseline and Weeks 1-12
A total of 682 participants who met the eligibility criteria at Screening (Visit 1) started a 28-day Run-in Period, in which they received open-label fluticasone propionate and salmeterol (FSC) 250/50 micrograms (µg), prior to being randomized to a 12-week randomized Treatment Period.
| Milestone | Placebo QD + FSC 250/50 µg BID | UMEC 62.5 µg QD + FSC 250/50 µg BID | UMEC 125 µg QD + FSC 250/50 µg BID |
|---|---|---|---|
| Started | 207 | 204 | 206 |
| Received randomized study medication | 205 | 204 | 205 |
| Completed | 178 | 190 | 184 |
| Not completed | 29 | 14 | 22 |
| Withdrew: Adverse event | 6 | 5 | 10 |
| Withdrew: Withdrew consent | 3 | 1 | 5 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 |
| Withdrew: Protocol deviation | 4 | 3 | 3 |
| Withdrew: Lack of efficacy | 11 | 5 | 3 |
| Withdrew: Protocol-defined stopping criteria | 1 | 0 | 0 |
| Withdrew: Randomized study medication not received | 2 | 0 | 1 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on Treatment Day 85 is defined as the mean of the FEV1 values obtained 23 and 24 hours after dosing on Treatment Day 84 (i.e., at Week 12). Baseline trough FEV1 is the mean of the two assessments made at -30 and -5 minutes (min) pre-dose on Treatment Day 1. Change from Baseline was calculated as the Day 85 value minus the Baseline value. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessments made at -30 and -5 min pre-dose on Treatment Day 1), smoking status, day, day by Baseline and day by treatment interactions.
| Liters | Placebo QD + FSC 250/50 µg BID | UMEC 62.5 µg QD + FSC 250/50 µg BID | UMEC 125 µg QD + FSC 250/50 µg BID |
|---|---|---|---|
| Change From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) on Day 85 | -0.022 ± 0.0146 | 0.125 ± 0.0142 | 0.116 ± 0.0144 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The weighted mean FEV1 was derived by calculating the area under the curve, and then dividing the value by the relevant time interval. The weighted mean was calculated using the 24-hour serial FEV1 measurements at Day 84, which included pre-dose, and post-dose at 15 min, 30 min, 1 hour, 3 hours, and 6 hours. Baseline trough FEV1 is the mean of the two assessments made at -30 and -5 min pre-dose on Treatment Day 1. Change from Baseline was calculated as the Day 84 value minus the Baseline value. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessments made at -30and -5 min pre-dose on Treatment Day 1), smoking status, day, day by Baseline and day by treatment interactions.
| Liters | Placebo QD + FSC 250/50 µg BID | UMEC 62.5 µg QD + FSC 250/50 µg BID | UMEC 125 µg QD + FSC 250/50 µg BID |
|---|---|---|---|
| Change From Baseline in Weighted Mean 0-6 Hour FEV1 Obtained Post-dose at Day 84 | 0.032 ± 0.0140 | 0.196 ± 0.0138 | 0.192 ± 0.0138 |
A rescue-free day is defined as a day on which no rescue medication was taken. Baseline calculations include a period of the later of 27 days before Visit 2 and the day after Visit 1, up to and including Day 1. The Weeks 1-12 calculations include a period from Study Day 2 up to the earlier of Study Day 85 and the day before Visit 7. Change from Baseline was calculated as the Weeks 1-12 value minus the Baseline value.
| Percentage of days | Placebo QD + FSC 250/50 µg BID | UMEC 62.5 µg QD + FSC 250/50 µg BID | UMEC 125 µg QD + FSC 250/50 µg BID |
|---|---|---|---|
| Change From Baseline in the Mean Percentage of Rescue-free Days Over Weeks 1-12 | 4.9 ± 25.66 | 13.3 ± 28.66 | 11.1 ± 25.70 |
The mean number of puffs per day of rescue albuterol/salbutamol at Baseline and on-treatment was recorded. The total puffs of rescue albuterol/salbutamol for each day was calculated as: (number of puffs + \[2 \* number of nebules\]). Baseline calculations include a period of the later of 27 days before Visit 2 and the day after Visit 1, up to and including Day 1. The Weeks 1-12 calculations include a period from Study Day 2 up to the earlier of Study Day 85 and the day before Visit 7. Change from Baseline was calculated as the Weeks 1-12 value value minus the Baseline value. Analysis was performed using an analysis of covariance (ANCOVA) model with covariates of treatment, Baseline (mean during the 4 weeks prior to Day 1), and smoking status.
| puffs | Placebo QD + FSC 250/50 µg BID | UMEC 62.5 µg QD + FSC 250/50 µg BID | UMEC 125 µg QD + FSC 250/50 µg BID |
|---|---|---|---|
| Change From Baseline in the Mean Number of Puffs Per Day of Rescue Albuterol/Salbutamol Over Weeks 1-12 | -0.2 ± 0.09 | -0.5 ± 0.09 | -0.5 ± 0.09 |
Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) are defined as those events occurring while participants were on treatment or those events with an onset during the follow-up period (up to 13 weeks).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo QD + FSC 250/50 µg BID | — | 8/205 (3.9%) | 21/205 (10.2%) |
| UMEC 62.5 µg QD + FSC 250/50 µg BID | — | 4/204 (2%) | 20/204 (9.8%) |
| UMEC 125 µg QD + FSC 250/50 µg BID | — | 6/205 (2.9%) | 22/205 (10.7%) |
| Event | Placebo QD + FSC 250/50 µg BID | UMEC 62.5 µg QD + FSC 250/50 µg BID | UMEC 125 µg QD + FSC 250/50 µg BID |
|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 3/205 | 2/204 | 1/205 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/205 | 1/204 | 0/205 |
| Vocal cord polypRespiratory, thoracic and mediastinal disorders | 0/205 | 1/204 | 0/205 |
| Duodenal ulcerGastrointestinal disorders | 0/205 | 1/204 | 0/205 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/205 | 1/204 | 0/205 |
| Chronic sinusitisInfections and infestations | 0/205 | 1/204 | 0/205 |
| PneumoniaInfections and infestations | 0/205 | 1/204 | 0/205 |
| Deep vein thrombosisVascular disorders | 0/205 | 1/204 | 0/205 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/205 | 0/204 | 1/205 |
| Cardio-respiratory arrestCardiac disorders | 0/205 | 0/204 | 1/205 |
| Event | Placebo QD + FSC 250/50 µg BID | UMEC 62.5 µg QD + FSC 250/50 µg BID | UMEC 125 µg QD + FSC 250/50 µg BID |
|---|---|---|---|
| HeadacheNervous system disorders | 10/205 | 9/204 | 13/205 |
| NasopharyngitisInfections and infestations | 10/205 | 5/204 | 5/205 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/205 | 7/204 | 5/205 |
| Age, Continuous(Years) | Placebo QD + FSC 250/50 µg BID | UMEC 62.5 µg QD + FSC 250/50 µg BID | UMEC 125 µg QD + FSC 250/50 µg BID | Total |
|---|---|---|---|---|
| Mean | 63.4 ± 8.27 | 62.7 ± 7.84 | 63.2 ± 8.95 | 63.1 ± 8.36 |
| Sex: Female, Male(Participants) | Placebo QD + FSC 250/50 µg BID | UMEC 62.5 µg QD + FSC 250/50 µg BID | UMEC 125 µg QD + FSC 250/50 µg BID | Total |
|---|---|---|---|---|
| Female | 73 | 71 | 63 | 207 |
| Male | 132 | 133 | 142 | 407 |
| Race/Ethnicity, Customized(Participants) | Placebo QD + FSC 250/50 µg BID | UMEC 62.5 µg QD + FSC 250/50 µg BID | UMEC 125 µg QD + FSC 250/50 µg BID | Total |
|---|---|---|---|---|
| African American/African Heritage | 4 | 5 | 3 | 12 |
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Japanese/East Asian Heritage/ South East Asian | 20 | 24 | 19 | 63 |
| White | 181 | 175 | 182 | 538 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Jan 2013, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Umeclidinium bromide
Pulmonary Disease, Chronic Obstructive →